17-N-Allylamino-17-demethoxygeldanamycin
| 17-N-Allylamino-17-demethoxygeldanamycin | |
|---|---|
 |
|
|
[(3S,5S,6R,7S,8E,10R,11S,12E,14E)-21- |
|
| Identifiers | |
| CAS number | 75747-14-7  |
| PubChem | 6440175 |
| ChemSpider | 21106220  |
| ChEMBL | CHEMBL109480 |
| Jmol-3D images | Image 1 Image 2 |
|
|
|
|
| Properties | |
| Molecular formula | C31H43N3O8 |
| Molar mass | 585.689 g/mol |
 (verify) (what is:  / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
 |
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (November 2011) |
17-N-Allylamino-17-demethoxygeldanamycin is a derivative of the antibiotic geldanamycin that is being studied in the treatment of cancer, specific young patients with certain types of leukemia or solid tumors, especially kidney tumors.
It works by targeting Hsp90, which is expressed in those tumors. It acts as an HSP inhibitor.
It belongs to the family of drugs called antitumor antibiotics.
[edit] Clinical trials
As of June 2005[update], 17-N-allylamino-17-demethoxygeldanamycin was undergoing Phase 1[1][2] and Phase 2 clinical trials.
[edit] References
- ^ http://www.clinicaltrials.gov/ct/show/NCT00093821 Phase 1 trial: 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
- ^ http://www.clinicaltrials.gov/ct/show/NCT00079404 Phase 1 trial : 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
[edit] External links
- National Cancer Institutie Bulletin on Phase 2 trials against Von Hippel-Lindau disease
- Safety sheet for 17AAG
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
